At $850000, price for new childhood blindness gene therapy four times too high, analysis says – Pharmacy Today, American Pharmacists Association, pharmacist.com
Genetic Literacy Project |
At $850000, price for new childhood blindness gene therapy four times too high, analysis says
Pharmacy Today, American Pharmacists Association, pharmacist.com voretigene neparvovec-rzyl (Luxturna—Spark Therapeutics), the first-of-its-kind gene therapy for a form of childhood blindness caused by a mutation in the RPE65 gene, is approximately four times too high for the value the drug provides. In a new … Report: Price for blindness gene therapy Luxturna is 'four times too high' at $850000 6 big medical advancements to expect in 2018 |
